Scientists at The Wistar Institute have solved a longstanding puzzle in ovarian cancer treatment: why anti-estrogen therapy often fails even when tumors express the hormone receptor that should make ...

Research from the Federal University of Rio de Janeiro (UFRJ) and the National Institute of Science and Technology for Structural Biology and Bioimaging (INBEB) in Brazil has uncovered a critical ...

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

Research by Rutgers Cancer Institute of New Jersey investigators shows the targeting of a binding protein of mutant p53 known as Rac1 could lead to new therapeutic strategies for patients whose cancer ...

“Our results provide unique insights into the mechanism of action of PG3 as a novel cancer therapeutic targeting p53 pathway-like tumor suppression” As highlighted in the abstract of this study, ...

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders' lab have uncovered a sinister hidden mechanism that can allow cancer cells to survive (and, in some cases, thrive) even when ...

Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute myeloid leukaemia (r/r AML) and myelodysplastic syndrome (MDS ...

Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on ...